Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001247276 | SCV001420688 | likely benign | Mucopolysaccharidosis type 1 | 2025-01-06 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002480846 | SCV002779883 | uncertain significance | Mucopolysaccharidosis, MPS-I-S; Hurler syndrome; Mucopolysaccharidosis, MPS-I-H/S | 2021-07-06 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003987813 | SCV004804390 | uncertain significance | not specified | 2024-01-11 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004034891 | SCV004885447 | uncertain significance | Inborn genetic diseases | 2023-12-08 | criteria provided, single submitter | clinical testing | The c.494G>A (p.G165D) alteration is located in exon 5 (coding exon 5) of the IDUA gene. This alteration results from a G to A substitution at nucleotide position 494, causing the glycine (G) at amino acid position 165 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001247276 | SCV002075292 | uncertain significance | Mucopolysaccharidosis type 1 | 2020-04-22 | no assertion criteria provided | clinical testing |